MIPH Stock Overview
Produces medicines, medical and dental supplies, and dietary supplements in Egypt and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MINAPHARM Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م159.18 |
| 52 Week High | ج.م294.70 |
| 52 Week Low | ج.م145.01 |
| Beta | -0.042 |
| 1 Month Change | -15.46% |
| 3 Month Change | 0.16% |
| 1 Year Change | -26.87% |
| 3 Year Change | 46.70% |
| 5 Year Change | 87.38% |
| Change since IPO | 1,650.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| MIPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -17.1% | -4.8% | -2.9% |
| 1Y | -26.9% | 24.9% | 18.3% |
Return vs Industry: MIPH underperformed the EG Pharmaceuticals industry which returned 26.6% over the past year.
Return vs Market: MIPH underperformed the EG Market which returned 19.9% over the past year.
Price Volatility
| MIPH volatility | |
|---|---|
| MIPH Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in EG Market | 8.8% |
| 10% least volatile stocks in EG Market | 3.2% |
Stable Share Price: MIPH's share price has been volatile over the past 3 months compared to the EG market.
Volatility Over Time: MIPH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of EG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | n/a | Wafik El Bardissi | www.minapharm.com |
MINAPHARM Pharmaceuticals produces medicines, medical and dental supplies, and dietary supplements in Egypt and internationally. The company produces veterinary and herbal medicines. It offers its products for the treatment of hematoma and thrombosis, iron deficiency anemia, recurrent urinary tract infections, immunostimulants, osteoporosis, renal osteodystrophy, loop diuretics, prophylaxis, hemorrhoids, rheumatoid arthritis, hyperlipidemia, alopecia, skin infections, topical corticosteroids, gynecological antifungals, vaginal infections, anti-infective, dyslipidemia, muscle spasm, dry eye, eye inflammation and allergy, corneal, nausea and vomiting, hepatology and gastroenterology, coronary heart, respiratory tract infections, occular irritation, labour induction, cerebral insufficiency, surgical dressing, prophylaxis, pregnancy and lactation, hemostasis, hemorrhage, infertility, glaucoma, ocular infection and inflammation, and microvascular diseases, as well as vitamin B12 deficiency, anemia, and diabetic neuropathy.
MINAPHARM Pharmaceuticals Fundamentals Summary
| MIPH fundamental statistics | |
|---|---|
| Market cap | ج.م1.76b |
| Earnings (TTM) | -ج.م190.31m |
| Revenue (TTM) | ج.م4.42b |
0.4x
P/S Ratio-9.3x
P/E RatioIs MIPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIPH income statement (TTM) | |
|---|---|
| Revenue | ج.م4.42b |
| Cost of Revenue | ج.م3.19b |
| Gross Profit | ج.م1.24b |
| Other Expenses | ج.م1.43b |
| Earnings | -ج.م190.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.20 |
| Gross Margin | 27.95% |
| Net Profit Margin | -4.30% |
| Debt/Equity Ratio | 114.1% |
How did MIPH perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield-10%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:12 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MINAPHARM Pharmaceuticals is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|